Small-molecule inhibitors of hepatitis C virus (HCV) non-structural protein 5A (NS5A): a patent review (2010-2015)

References

• Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483–1493.
   PubMed Web of Science ®Google Scholar
• De Clercq E, Li G. Approved antiviral drugs over the past 50 years. Clin Microbiol Rev. 2016;29:695–747.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Hepatitis C WHO fact sheet no. 164. 2015. Available from: http://www.who.int/mediacentre/factsheets/fs164_apr2014/en/
   Google Scholar
• Cacoub P, Gragnani L, Comarmond C, et al. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis. 2014;46(Suppl 5):S165–S173.
   PubMedGoogle Scholar
• Center for Disease Control and Prevention. Hepatitis C information. Available from: http://www.cdc.gov/hepatitis/hcv
   Google Scholar
• Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61:S45–S57.
   PubMed Web of Science ®Google Scholar
• Chen T, Terrault N. Treatment of chronic hepatitis C in patients with cirrhosis. Curr Opin Gastroenterol. 2016;32:143–151.
   PubMed Web of Science ®Google Scholar
• Maan R, Van Der Meer AJ. Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease. F1000Res. 2016;5:367.
   Google Scholar
• Nakamoto S, Kanda T, Shirasawa H, et al. Antiviral therapies for chronic hepatitis C virus infection with cirrhosis. World J Hepatol. 2015;7:1133–1141.
   PubMedGoogle Scholar
• Coppola N, Minichini C, Starace M, et al. Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals. J Med Virol. 2016;88:1659–1671.
   PubMed Web of Science ®Google Scholar
• Vernaz N, Girardin F, Goossens N, et al. Drug pricing evolution in hepatitis C. PloS One. 2016;11:e0157098.
   Google Scholar
• Garagiola E, Ferrario L, Croce D, et al. HCV novel therapeutic regimens in Wonderland: a budget impact analysis in the Lombardy Region. Dig Liver Dis. 2016;48:1200–1207.
   PubMedGoogle Scholar
• Gentile I, Buonomo AR, Zappulo E, et al. Discontinued drugs in 2012-2013: hepatitis C virus infection. Expert Opin Investig Drugs. 2015;24:239–251.
   PubMed Web of Science ®Google Scholar
• Ross-Thriepland D, Harris M. Hepatitis C virus NS5A: enigmatic but still promiscuous 10 years on!. J Gen Virol. 2015;96:727–738.
   PubMed Web of Science ®Google Scholar
• Siu GK, Zhou F, Yu MK, et al. Hepatitis C virus NS5A protein cooperates with phosphatidylinositol 4-kinase IIIalpha to induce mitochondrial fragmentation. Sci Rep. 2016;6:23464.
   PubMed Web of Science ®Google Scholar
• Fiches GN, Eyre NS, Aloia AL, et al. HCV RNA traffic and association with NS5A in living cells. Virology. 2016;493:60–74.
   PubMed Web of Science ®Google Scholar
• Eyre NS, Hampton-Smith RJ, Aloia AL, et al. Phosphorylation of NS5A serine-235 is essential to hepatitis C virus RNA replication and normal replication compartment formation. Virology. 2016;491:27–44.
   PubMed Web of Science ®Google Scholar
• Gale MJ Jr., Korth MJ, Tang NM, et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology. 1997;230:217–227.
   PubMed Web of Science ®Google Scholar
• Polyak SJ, Khabar KS, Paschal DM, et al. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J Virol. 2001;75:6095–6106.
   PubMed Web of Science ®Google Scholar
• Szabo G. Hepatitis C virus NS5A protein–a master regulator?. Gastroenterology. 2006;130:995–999.
   PubMed Web of Science ®Google Scholar
• Ross-Thriepland D, Mankouri J, Harris M. Serine phosphorylation of the hepatitis C virus NS5A protein controls the establishment of replication complexes. J Virol. 2015;89:3123–3135.
   PubMed Web of Science ®Google Scholar
• Schmitz U, Tan SL. NS5A–from obscurity to new target for HCV therapy. Recent Pat Antiinfect Drug Discov. 2008;3:77–92.
   PubMedGoogle Scholar
• Meistermann H, Gao J, Golling S, et al. A novel immuno-competitive capture mass spectrometry strategy for protein-protein interaction profiling reveals that LATS kinases regulate HCV replication through NS5A phosphorylation. Mol Cell Proteomics. 2014;13:3040–3048.
   PubMed Web of Science ®Google Scholar
• Ross-Thriepland D, Harris M. Insights into the complexity and functionality of hepatitis C virus NS5A phosphorylation. J Virol. 2014;88:1421–1432.
   PubMed Web of Science ®Google Scholar
• Ivanenkov YA, Veselov MS, Shakhbazyan AG, et al. A comprehensive insight into the chemical space and ADME features of small molecule NS5A inhibitors. Curr Top Med Chem. 2016;16:1372–1382.
   PubMed Web of Science ®Google Scholar
• Ivanenkov YA, Veselov MS, Aladinskiy VA, et al. In silico approaches to the design of NS5A inhibitors. Curr Top Med Chem. 2016;16:1383–1391.
   PubMed Web of Science ®Google Scholar
• Zhang X. Direct anti-HCV agents. Acta Pharm Sin B. 2016;6:26–31.
   PubMed Web of Science ®Google Scholar
• Bonamassa B, Ciccarese F, Antonio VD, et al. Hepatitis C virus and host cell nuclear transport machinery: a clandestine affair. Front Microbiol. 2015;6:619.
   PubMed Web of Science ®Google Scholar
• Tamori A, Enomoto M, Kawada N. Recent advances in antiviral therapy for chronic hepatitis C. Mediators of Inflammation. 2016;2016:1–11.
   Web of Science ®Google Scholar
• Gotte M, Feld JJ. Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights. Nat Rev Gastroenterol Hepatol. 2016;13:338–351.
   PubMed Web of Science ®Google Scholar
• Banerjee D, Reddy KR. Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy. Aliment Pharmacol Ther. 2016;43:674–696.
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Lawitz E, Poordad F, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med. 2014;370:222–232.
   PubMed Web of Science ®Google Scholar
• Asselah T, Boyer N, Saadoun D, et al. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int. 2016;36(Suppl 1):47–57.
   PubMed Web of Science ®Google Scholar
• Nakamoto S, Kanda T, Wu S, et al. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol. 2014;20:2902–2912.
   PubMed Web of Science ®Google Scholar
• Cheng G, Yu M, Peng B, et al. GS-5816, a second generation HCV NS5A inhibitor with potent antiviral activity, broad genotypic coverage and a high resistance barrier. J Hepatol. 2013;58(Suppl 1):S484–S485.
   Google Scholar
• Yang G, Wiles J, Patel D, et al. Preclinical characteristics of ACH-3102: a novel HCV NS5A inhibitor with improved potency against genotype-1a virus and variants resistant to 1st generation of NS5A inhibitors. J Hepatol. 2012;56(Suppl 2):S330.
   Google Scholar
• Liu R, Kong R, Mann P, et al. In vitro resistance analysis of HCV NS5A inhibitor: MK-8742 demonstrates increased potency against clinical resistance variants and higher resistance barrier. J Hepatol. 2012;56(Suppl 2):S334–S335.
   Google Scholar
• Dwyer MP, Keertikar KM, Chen L, et al. Matched and mixed cap derivatives in the tetracyclic indole class of HCV NS5A inhibitors. Bioorg Med Chem Lett. 2016;26:4106–4111.
   PubMed Web of Science ®Google Scholar
• Yu W, Coburn CA, Nair AG, et al. Aryl or heteroaryl substituted aminal derivatives of HCV NS5A inhibitor MK-8742. Bioorg Med Chem Lett. 2016;26:3414–3420.
   PubMed Web of Science ®Google Scholar
• Nair AG, Zeng Q, Selyutin O, et al. Discovery of silyl proline containing HCV NS5A inhibitors with pan-genotype activity: SAR development. Bioorg Med Chem Lett. 2016;26:1475–1479.
   PubMedGoogle Scholar
• Wang NY, Xu Y, Zuo WQ, et al. Discovery of imidazo[2,1-b]thiazole HCV NS4B inhibitors exhibiting synergistic effect with other direct-acting antiviral agents. J Med Chem. 2015;58:2764–2778.
   PubMed Web of Science ®Google Scholar
• Henderson JA, Bilimoria D, Bubenik M, et al. Benzimidazole-containing HCV NS5A inhibitors: effect of 4-substituted pyrrolidines in balancing genotype 1a and 1b potency. Bioorg Med Chem Lett. 2015;25:944–947.
   PubMed Web of Science ®Google Scholar
• Henderson JA, Bilimoria D, Bubenik M, et al. Synthesis and evaluation of NS5A inhibitors containing diverse heteroaromatic cores. Bioorg Med Chem Lett. 2015;25:948–951.
   PubMedGoogle Scholar
• Nettles JH, Stanton RA, Broyde J, et al. Asymmetric binding to NS5A by daclatasvir (BMS-790052) and analogs suggests two novel modes of HCV inhibition. J Med Chem. 2014;57:10031–10043.
   PubMed Web of Science ®Google Scholar
• Conte I, Giuliano C, Ercolani C, et al. Synthesis and SAR of piperazinyl-N-phenylbenzamides as inhibitors of hepatitis C virus RNA replication in cell culture. Bioorg Med Chem Lett. 2009;19:1779–1783.
   PubMed Web of Science ®Google Scholar
• Thomson Reuters Integrity Database. Available from: https:\\integrity.thomson-pharma.com
   Google Scholar
• SciFinder, Chemical Abstracts Service. Available from: http://www.cas.org
   Google Scholar
• Hopwood M, Treloar C. Pretreatment preparation and management of interferon-based therapy for hepatitis C virus infection. J Adv Nurs. 2007;59:248–254.
   PubMed Web of Science ®Google Scholar
• Erim Y, Tagay S, Beckmann M, et al. Depression and protective factors of mental health in people with hepatitis C: a questionnaire survey. Int J Nurs Stud. 2010;47:342–349.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Hepatitis C information for health professionals 2013. Available from: http://www.cdc.gov/hepatitis/hcv/hcvfaq.htm
   Google Scholar
• Sockalingam S, Blank D, Al Jarad A, et al. A comparison of depression screening instruments in hepatitis C and the impact of depression on somatic symptoms. Psychosomatics. 2011;52:433–440.
   PubMed Web of Science ®Google Scholar
• Kinder M. The lived experience of treatment for hepatitis C. Gastroenterol Nurs. 2009;32:401–408.
   PubMed Web of Science ®Google Scholar
• Hamza I, Eid Y, El-Sayed M, et al. Thyroid dysfunction in chronic hepatitis C patients treated with the combined pegylated interferon-ribavirin therapy. J Interferon Cytokine Res. 2016;36:527–533.
   Web of Science ®Google Scholar
• Medhat E, Esmat G, Hamza E, et al. Ophthalmological side effects of interferon therapy of chronic hepatitis C. Hepatobiliary Surg Nutr. 2016;5:209–216.
   PubMed Web of Science ®Google Scholar
• Rehman AU, Ali F, Ali M, et al. Changes in hematological parameters with pegylated interferon in chronic hepatitis C virus infected patients. Asian Pac J Cancer Prev. 2016;17:2485–2490.
   PubMedGoogle Scholar
• Huang LL, Sung HY, Liu LF, et al. Distress, depression and quality of life in patients with chronic hepatitis C treated with interferon and ribavirin. J Nurs Healthcare Res. 2010;6:183–190.
   Google Scholar
• Redulla R, Dudley-Brown S. Adherence and completion in hepatitis C management: a systematic review. Gastroenterol Nurs. 2013;36:53–58.
   PubMed Web of Science ®Google Scholar
• Squibb B-M. Inhibitors of HCV replication. WO2006133326. 2006.
   Google Scholar
• Squibb B-M. Hepatitis C virus assays. WO2004015131. 2004.
   Google Scholar
• Squibb B-M. Combination pharmaceutical agents as inhibitors of HCV replication. WO2004014313. 2004.
   Google Scholar
• Squibb B-M. Iminothiazolidinones as inhibitors of HCV replication. WO2004014852. 2004.
   Google Scholar
• Squibb B-M. Hepatitis C virus inhibitors. US20160067223. 2016.
   Google Scholar
• Smith MA, Regal RE, Mohammad RA. Daclatasvir: a NS5A replication complex inhibitor for hepatitis C infection. Ann Pharmacother. 2016;50:39–46.
   PubMed Web of Science ®Google Scholar
• Belema M, Meanwell NA. Discovery of daclatasvir, a pan-genotypic hepatitis C virus NS5A replication complex inhibitor with potent clinical effect. J Med Chem. 2014;57:5057–5071.
   PubMed Web of Science ®Google Scholar
• Squibb B-M. Hepatitis C virus NS5A inhibitors. WO2008021927. 2008.
   Google Scholar
• Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010;465:96–100.
   PubMed Web of Science ®Google Scholar
• Bartenschlager R, Pietschmann T. Efficient hepatitis C virus cell culture system: what a difference the host cell makes. Proc Natl Acad Sci U S A. 2005;102:9739–9740.
   PubMed Web of Science ®Google Scholar
• Ivachtchenko AV, Mitkin OD, Yamanushkin PM, et al. Discovery of novel highly potent hepatitis C virus NS5A inhibitor (AV4025). J Med Chem. 2014;57:7716–7730.
   PubMed Web of Science ®Google Scholar
• Stirnimann G. Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C. Expert Opin Pharmacother. 2014;15:2609–2622.
   PubMed Web of Science ®Google Scholar
• Sciences G Inc., Harvoni prescribing information 2015. Available from: http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf
   Google Scholar
• Wong KA, Worth A, Martin R, et al. Characterization of hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885. Antimicrob Agents Chemother. 2013;57:6333–6340.
   PubMed Web of Science ®Google Scholar
• Lawitz EJ, Gruener D, Hill JM, et al. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol. 2012;57:24–31.
   PubMed Web of Science ®Google Scholar
• Bourliere M, Adhoute X, Ansaldi C, et al. Sofosbuvir plus ledipasvir in combination for the treatment of hepatitis C infection. Expert Rev Gastroenterol Hepatol. 2015;9:1483–1494.
   PubMed Web of Science ®Google Scholar
• Raedler LA. Once-a-day harvoni (ledipasvir plus sofosbuvir), a new oral combination for the treament of patients with genotype 1 chronic hepatitis C infection. Am Health Drug Benefits. 2015;8:54–58.
   PubMedGoogle Scholar
• Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015;313:1232–1239.
   PubMed Web of Science ®Google Scholar
• O’Boyle DR 2nd, Nower PT, Gao M, et al. Synergistic activity of combined NS5A inhibitors. Antimicrob Agents Chemother. 2016;60:1573–1583.
   Web of Science ®Google Scholar
• Pol S, Corouge M, Vallet-Pichard A. Daclatasvir-sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life. Hepat Med. 2016;8:21–26.
   PubMed Web of Science ®Google Scholar
• Kumari R, Nguyen MH. Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1. Expert Opin Pharmacother. 2015;16:739–748.
   PubMed Web of Science ®Google Scholar
• Alexopoulou A, Karayiannis P. Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals. Ann Gastroenterol. 2015;28:55–65.
   PubMedGoogle Scholar
• Welzel TM, Dultz G, Zeuzem S. Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors. J Hepatol. 2014;61:S98–S107.
   Google Scholar
• Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014;371:2375–2382.
   PubMed Web of Science ®Google Scholar
• Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373:2608–2617.
   PubMed Web of Science ®Google Scholar
• Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373:2599–2607.
   PubMed Web of Science ®Google Scholar
• A 4-drug combination (Viekira Pak) for hepatitis C. Med Lett Drugs Ther. 2015;57:15–17.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Makara M, Akarca US, et al. Efficacy and safety of ombitasvir, paritaprevir, and ritonavir in an open-label study of patients with genotype 1b chronic hepatitis C virus infection with and without cirrhosis. Gastroenterology. 2015;149:971–980 e1.
   PubMed Web of Science ®Google Scholar
• A study to evaluate the efficacy and safety of experimental drugs ABT-493/ABT-530 in adults with chronic hepatitis C virus genotype 1-6 infection and human immunodeficiency virus - 1 coinfection. ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT02738138
   Google Scholar
• Muir AJ, Poordad F, Lalezari J, et al. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. 2015;313:1736–1744.
   PubMed Web of Science ®Google Scholar
• Keating GM. Elbasvir/grazoprevir: first global approval. Drugs. 2016;76:617–624.
   PubMed Web of Science ®Google Scholar
• Kohler JJ, Nettles JH, Amblard F, et al. Approaches to hepatitis C treatment and cure using NS5A inhibitors. Infect Drug Resist. 2014;7:41–56.
   PubMed Web of Science ®Google Scholar
• Hezode C, Hirschfield GM, Ghesquiere W, et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut. 2015;64:948–956.
   PubMed Web of Science ®Google Scholar
• Suzuki F, Toyota J, Ikeda K, et al. A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection. Antivir Ther. 2014;19:491–499.
   PubMed Web of Science ®Google Scholar
• Izumi N, Yokosuka O, Kawada N, et al. Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1. Antivir Ther. 2014;19:501–510.
   PubMed Web of Science ®Google Scholar
• European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63:199–236.
   PubMed Web of Science ®Google Scholar
• AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932–954.
   PubMed Web of Science ®Google Scholar
• Colombo M. Interferon-free therapy for hepatitis C: the hurdles amid a golden era. Dig Liver Dis. 2015;47:727–733.
   PubMedGoogle Scholar
• Ahmed A, Felmlee DJ. Mechanisms of hepatitis C viral resistance to direct acting antivirals. Viruses. 2015;7:6716–6729.
   PubMed Web of Science ®Google Scholar
• Andre-Garnier E, Ribeyrol O, Gournay J, et al. Emergence of HCV resistance-associated variants in patients failing sofosbuvir-based regimens: an observational cohort. Antivir Ther. 2016;21:611–619.
   PubMedGoogle Scholar
• Calleja JL, Llerena S, Perello C, et al. NS5A resistance: clinical implications and treatment possibilities. AIDS Rev. 2016;18:15–22.
   PubMed Web of Science ®Google Scholar
• Peres-da-Silva A, De Almeida AJ, Lampe E. NS5A inhibitor resistance-associated polymorphisms in Brazilian treatment-naive patients infected with genotype 1 hepatitis C virus. J Antimicrob Chemother. 2015;70:726–730.
   PubMed Web of Science ®Google Scholar
• Nguyen LT, Hall N, Sheerin D, et al. Naturally occurring HCV NS5A/B inhibitor resistance-associated mutations to direct-acting antivirals. Antivir Ther. 2016;21:447–453.
   Google Scholar
• Pawlotsky JM. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology. 2016;151:70–86.
   PubMed Web of Science ®Google Scholar
• Cento V, Chevaliez S, Perno CF. Resistance to direct-acting antiviral agents: clinical utility and significance. Curr Opin HIV AIDS. 2015;10:381–389.
   PubMed Web of Science ®Google Scholar
• Issur M, Gotte M. Resistance patterns associated with HCV NS5A inhibitors provide limited insight into drug binding. Viruses. 2014;6:4227–4241.
   PubMed Web of Science ®Google Scholar
• Roche B, Coilly A, Roque-Afonso AM, et al. Interferon-free hepatitis C treatment before and after liver transplantation: the role of HCV drug resistance. Viruses. 2015;7:5155–5168.
   PubMed Web of Science ®Google Scholar
• Wang C, Sun J-H, O’Boyle DR 2nd, et al. Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir. Antimicrob Agents Chemother. 2013;57:2054–2065.
   PubMed Web of Science ®Google Scholar
• Sun J-H, O’Boyle DR 2nd, Fridell RA, et al. Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A. Nature. 2015;527:245–248.
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Martin P, Messa P. New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant. Kidney Int. 2016;89:988–994.
   PubMed Web of Science ®Google Scholar
• Wanchoo R, Thakkar J, Schwartz D, et al. Harvoni (ledipasvir with sofosbuvir)-induced renal injury. Am J Gastroenterol. 2016;111:148–149.
   PubMed Web of Science ®Google Scholar
• Novartis A Dimeric iap inhibitors. US20130266590. 2013.
   Google Scholar